Disseminated on behalf of  ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF)and may include paid advertising.

• Canadian near-term precious metal producer ESGold is advancing toward the May start of a drill program expected to further define priority targets on its 20,618-hectare Montauban Gold-Silver Project in Quebec
• The company is simultaneously working to construct a fully permitted mill on site and expand the scope of its exploration
• ESGold is employing a low CapEx strategy that includes funding from a private placement initiative and an agreement with Ocean Partners UK Ltd. that provides a credit facility and a dedicated buyer of gold and silver produced from its planned tailings cleanup operation
• Despite market fluctuations, gold has effectively doubled in value since January 2025 and is expected to remain at near-record levels in the coming months, benefiting companies positioned to provide supply for continued demand

Clean process near-term gold and silver production company ESGold (CSE: ESAU) (OTCQB: ESAUF) is completing preparations for anticipated drilling operations in May at its Montauban Gold-Silver Project in Quebec while simultaneously progressing toward mill construction and an expanded exploration footprint. 

“We are fully funded to execute on this plan, and our focus is on disciplined execution across both development and exploration as we move through what we believe will be a very important period for the company,” ESGold CEO Gordon Robb stated in a news release earlier this month (https://ibn.fm/07Mcq).

ESGold is employing a tailings-cleanup-to-cash-flow model to generate revenues that can then be reinvested in the company’s operations, paving the way for new exploration at the site. 

“We are fully permitted for a thousand-ton-per-day [mill] operation. We’re fully funded to build the thousand-ton-per-day facility and we will be generating revenue to fund further exploration and development of the past-producing Montauban asset,” Robb added during an interview at the March Swiss Mining Institute (“SMI”) conference in Switzerland with conference Chairman Carlos Vargas (https://ibn.fm/o0odT).

“We have material sitting on surface. … If we can extract that economic value while cleaning up these tailings, it puts us in a very enviable position to be generating cash flow,” he added. “We have equipment arriving onsite. That building is complete. … We’re looking to be cash-flowing by the year-end.”

ESGold inked a C$9 million binding term sheet with Ocean Partners UK Ltd. last year that provides a credit facility to the company, while Ocean Partners buys the gold and silver dore produced from Montauban tailings and crown pillar material. The company had access to the first C$3 million tranche in February, while the remaining C$6 million will be available in a second tranche approximately five months before Phase 2 production, which is currently expected to begin next March. 

The targeted drill program will test zones identified as high potential areas by ESGold’s expanded Ambient Noise Tomography (“ANT”) imaging as well as data from historical drilling and detailed structural interpretation. 

“This is a past-producing asset that was never properly explored,” Robb said in the SMI interview. “The deepest drill hole went down to about 200 meters at depth. It was never drilled to the north [or] the south. We wanted to get a better idea of what we’re looking at, so we did an ANT survey coupled with a VTEM (Versatile Time Domain Electromagnetic) survey and we put together a 3-D model. … What we saw was something a lot bigger than originally anticipated. We found structure down to 900 meters at depth to the strike that looked [at least] 2 kilometers at length. It really excited our geologists and gave us a lot of targets.”

The program aims to determine if the mineralized corridor continues across the broader land package and to further define the scale and structural framework of the Montauban system, which spans 417 mining claims and 20,618 contiguous hectares (about 50,948 acres) across the Montauban and Chavigny townships west of Quebec City (https://ibn.fm/c2bvN).

“[The mill construction, ANT survey and drill program] are foundational steps, and they are all advancing at the same time. What is particularly exciting is how these initiatives come together. We are moving toward production while, in parallel, expanding our understanding of what we believe could be a much larger system,” Robb stated in the news release. 

Gold has enjoyed a massive surge in spot value since the beginning of the current U.S. administration, and while recent market fluctuations have brought gold back from its record peak in March the precious metal continues to enjoy a price level nearly double where it was in January 2025, creating optimism for gold sector producers positioned to provide supply for demand.

For more information, visit the company’s website at https://esgold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF

• Soligenix reports clinical update centered on cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin lymphoma that primarily affects the skin.
• The interim update highlighted that the overall blinded aggregate response rate observed in patients who have completed treatment remains consistent with prior reporting.
• In addition, the company reported positive results from a study evaluating HyBryte(TM) against Valchlor(R), an existing treatment option for cutaneous T-cell lymphoma.

Advancing clinical research while generating positive data is a critical combination in biotechnology, particularly when addressing diseases with limited treatment options. Soligenix (NASDAQ: SNGX) is demonstrating that momentum as it provides  both an encouraging clinical update from its phase 3 FLASH2 study and positive comparative clinical results for its HyBryte therapy, reinforcing the company’s focus on developing innovative treatments for serious conditions.

The research highlighted in these announcements centers on cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin lymphoma that primarily affects the skin. According to the National Cancer Institute, CTCL can cause persistent skin lesions, plaques and tumors, often leading to significant discomfort and reduced quality of life. The disease is typically chronic and may require long-term treatment, making the development of effective and well-tolerated therapies particularly important.

Treatment options for CTCL remain limited, especially in early-stage disease where therapies are often used off-label or associated with notable side effects. The American Cancer Society notes that treatments such as phototherapy, topical therapies and systemic approaches are commonly used to manage symptoms of CTCL, although their effectiveness can vary and may not provide durable responses for all patients. In addition, some of these therapies carry risks with prolonged use, including skin irritation, damage and an increased risk of secondary skin cancers, underscoring the need for safer and more targeted treatment options.

The burden of the disease extends beyond physical symptoms. Chronic skin involvement, visible lesions and recurring flares can have a meaningful impact on quality of life, affecting both physical comfort and emotional well-being. As a result, ongoing research into therapies that can provide sustained efficacy with improved tolerability is considered a priority within the oncology and dermatology communities.

Against this backdrop, Soligenix has reported progress across two recent developments involving HyBryte, its investigational photodynamic therapy for CTCL. The company is continuing its phase 3 FLASH2 clinical trial, with an interim analysis expected in the second quarter of 2026 and topline results anticipated in the second half of the year. This late-stage study is designed to further evaluate the safety and efficacy of HyBryte following earlier clinical success.

The clinical update also highlighted that the overall blinded aggregate response rate observed in patients who have completed treatment remains consistent with prior reporting at approximately 48%, compared to a 25% response rate used to design the study. This difference is significant because it suggests that the therapy may be performing above initial expectations; final conclusions will depend on the unblinded data and full study results.

In addition, Soligenix reported positive results from a comparative study evaluating HyBryte against Valchlor, an existing treatment option for CTCL. The study measured outcomes over a 12-week treatment period and focused on defined improvements in disease severity.

According to the reported data, 60% of patients treated with HyBryte achieved the defined level of treatment success, compared to 20% of patients treated with Valchlor. The average cumulative improvement in disease severity scores was 52.5% in the HyBryte group compared to 34.7% in the Valchlor group, indicating a potentially stronger treatment effect.

The safety profile observed in the study further differentiates the therapy. HyBryte was reported to be well tolerated among treated patients, while a portion of patients receiving Valchlor experienced treatment-related adverse events, including skin reactions such as dermatitis and sensitivity at the application site. These findings are important because tolerability is a key consideration in chronic conditions that require ongoing treatment.

HyBryte is based on a photodynamic therapy approach that combines a light-activated compound with controlled exposure to visible light. This mechanism allows for targeted treatment of affected skin areas while minimizing systemic exposure, which may contribute to its favorable safety profile.

Together, the Phase 3 clinical update and comparative study results provide a clearer picture of HyBryte’s potential role in the treatment landscape for CTCL. The combination of encouraging efficacy signals and a favorable tolerability profile suggests that the therapy could address some of the limitations associated with existing treatments, particularly if these findings are confirmed in larger studies.

As Soligenix continues to advance its clinical programs, the data emerging from these studies highlight the importance of sustained research and innovation in rare and challenging diseases. With additional clinical milestones expected in 2026, the company’s progress reflects both the complexity of drug development and the potential impact of new therapeutic approaches on patient care.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

• Oncotelic Therapeutics has recently entered a strategic partnership with TechForce Robotics to commercialize a PDAOAI-enhanced, GMP-compliant robotics platform
• The collaboration integrates AI-driven compliance systems with advanced robotics for pharmaceutical manufacturing automation
• This pivot underscores a broader strategy: extending Oncotelic’s AI capabilities beyond therapeutics into scalable, high-value industrial applications

Oncotelic Therapeutics (OTCQB: OTLC) is signaling a significant strategic evolution, moving beyond its roots as a clinical-stage biotechnology company into the quickly expanding intersection of artificial intelligence and industrial automation. Through two closely aligned announcements, the firm has unveiled a strategic partnership with TechForce Robotics, which positions it to commercialize a next-generation, AI-enhanced platform created for regulated pharmaceutical environments (ibn.fm/aA1Bt).

At the core of this pivot is Oncotelic’s proprietary PDAOAI platform, an AI-driven system designed to improve compliance, monitoring, and operational intelligence. By integrating this innovation with TechForce Robotics’ hardware and manufacturing expertise, the companies aim to deliver a GMP-compliant robotics solution capable of automating critical workflows in pharmaceutical production and laboratory settings.

The newly announced platform is already deployed within strict GMP (Good Manufacturing Practice) environments and is currently addressing one of the most common challenges in biopharma manufacturing: maintaining regulatory compliance while scaling production. Through automated material handling, real-time monitoring, and AI-enabled deviation detection, the system is expected to cut down on human intervention, reduce contamination risks, and improve process consistency.

OTLC’s partnership with TechForce formalizes this effort through a joint development, manufacturing, and licensing agreement, creating a structured pathway toward commercialization. This isn’t just a research collaboration; it represents a coordinated go-to-market strategy aimed at deploying a scalable, intelligent automation system across pharmaceutical and potentially adjacent regulated industries (ibn.fm/zymOX).

From the perspective of an investor, this shift is particularly noteworthy. While Oncotelic continues to advance its therapeutic pipeline, including TGF-beta-focused treatments targeting orphan diseases and high unmet medical needs, the integration of AI and robotics introduces a parallel revenue pathway that is less dependent on the long timelines and binary risks associated with drug development.

This strategic rationale becomes even clearer when viewed against broader industry dynamics. Pharmaceutical manufacturers are under increasing pressure to improve efficiency, ensure compliance, and reduce reliance on manual processes. AI-enhanced automation is emerging as a critical solution layer, and Oncotelic’s PDAOAI platform is designed specifically to address these needs through data-driven, intelligent workflows.

The complementary nature of the partnership is central to its potential success. TechForce Robotics contributes advanced engineering, scalable manufacturing, and capabilities and deployment infrastructure, while Oncotelic provides domain expertise in biotechnology and AI-enhanced pharmaceutical processes. This alignment enables the combined platform to move more rapidly from concept to commercialization, speeding up time-to-market in a sector where demand for automation is growing (ibn.fm/raqL2).

Leadership also plays a critical role in underpinning this initiative. CEO, Dr. Vuong Trieu, brings decades of experience across oncology, drug development, and AI applications in healthcare, strategically positioning Oncotelic to bridge the gap between scientific innovation and industrial implementation. His background strengthens the company’s ability to translate complex biomedical and regulatory requirements into scalable technology solutions.

Importantly, the transition does not represent a departure from Oncotelic’s core mission but rather an expansion of it. By leveraging its AI capabilities beyond therapeutics, the company is creating a broader innovation platform that spans both drug development and the needed infrastructure required to manufacture those therapies efficiently and compliantly.

For investors, Oncotelic Therapeutics now represents a dual opportunity: exposure to a clinical-stage biotech pipeline alongside a scalable, AI-driven automation platform aimed at high-demand industrial use cases. This strategic diversification could enhance long-term value creation while mitigating some of the inherent risks associated with traditional biotech development cycles.

For more information, visit the company’s website at www.Oncotelic.com.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC

• American Fusion(TM) used the 2026 ARPA-E Energy Innovation Summit to advance its commercial strategy and expand relationships across the fusion ecosystem.
• The company is developing innovational decentralized fusion technologies through its wholly owned subsidiary, Kepler Fusion Technologies, centered on the Texatron(TM) platform, targeting data center operators and developers as an initial customer base for future power deployment.
• American Fusion(TM) is pursuing supply chain relationships for key fusion inputs including helium-3 and deuterium and is also evaluating a potential Frankfurt Stock Exchange listing as part of a broader capital markets strategy.

American Fusion(TM) (OTC: AMFN), a developer of next-generation fusion energy technologies, is seeking to establish its place within the increasingly competitive fusion energy sector by sharpening its commercialization strategy, building institutional relationships, and refining its long-term market positioning.

The company, which recently rebranded from Renewal Fuels following its merger with Kepler Fusion Technologies, participated in the 2026 ARPA-E Energy Innovation Summit, a U.S. Department of Energy-backed gathering widely viewed as one of the most prominent annual forums for emerging energy technologies (https://ibn.fm/k5sD0).

According to a company news release, the summit provided American Fusion(TM) an opportunity to engage directly with government stakeholders, technical institutions, investors and other fusion developers while assessing the sector’s evolving competitive landscape.

Fusion energy has drawn growing public and private investment in recent years as governments and corporations search for long-term clean energy alternatives capable of delivering reliable baseload electricity. The sector includes well-funded private developers such as Commonwealth Fusion Systems, Helion Energy and TAE Technologies, all of which were represented at the ARPA-E summit. While most fusion companies remain in developmental stages, competition has intensified around which technologies may ultimately prove commercially viable.

American Fusion(TM) is pursuing a strategy built around its Texatron(TM) fusion platform, an aneutronic fusion design under development by Kepler Fusion Technologies. Management describes the system as focusing on compact and modular architecture, direct energy conversion, and scalable deployment for industrial and infrastructure applications. Although the technology remains under development, the company is working to differentiate itself by emphasizing deployment flexibility and infrastructure-focused applications rather than solely long-term utility-scale grid replacement.

At the ARPA-E summit, American Fusion(TM) said it held meetings with multiple U.S. government and research organizations, including representatives from the U.S. Navy, Naval Nuclear Laboratory and Naval Research Laboratory. The company also met with Department of Energy officials, national laboratories and university partners as it seeks to broaden technical collaboration and potential funding opportunities.

American Fusion(TM) additionally reported evaluating public-private financing opportunities and strategic partnerships that may support long-term development. While no funding agreements were announced, the company’s participation reflects a broader trend across the fusion sector, where many early-stage developers are seeking to pair private capital with government-backed innovation support.

One of the clearest developments from the summit was the company’s articulation of its first commercial target market. American Fusion(TM) said it has identified data center developers and operators as an initial target customer segment, particularly those requiring behind-the-meter power solutions and long-term electricity agreements.

The rationale reflects rising global electricity demand tied to artificial intelligence, cloud computing and next-generation data infrastructure. Data centers increasingly require dense, uninterrupted power supply, and many operators are exploring alternative generation methods as grid constraints and electricity demand rise. Management believes fusion-based systems, if successfully commercialized, could eventually provide high-density on-site power generation for such facilities.

Chief Executive Richard Hawkins noted that reliable and affordable electricity is becoming a central issue across computing infrastructure, particularly as operators seek secure power sources for energy-intensive facilities. “Securing the underlying components and inputs required to support that delivery is not straightforward. This is not an easy supply chain to establish at scale, and the progress we are making across commercial strategy and supply chain development represents a meaningful step forward,” Hawkins said.

Alongside commercial planning, American Fusion(TM) is also evaluating long-term supply chain requirements needed to support eventual deployment. That includes sourcing of fusion fuel inputs such as helium-3 and deuterium, materials critical to the company’s intended fusion process. Management has indicated that establishing dependable access to those materials will be an important part of long-term scaling efforts.

To support that strategy, the company is considering a potential dual listing on the Frankfurt Stock Exchange, which management believes could improve access to European capital markets and strengthen alignment with international suppliers and industrial partners. The company has also noted that certain helium-3 sourcing opportunities may be more accessible through European-linked supply channels, though no definitive agreements have yet been announced.

“As we move from development toward execution, establishing the right supply chain relationships becomes increasingly important,” said Brent Nelson, CEO of Kepler Fusion Technologies. “Access to reliable inputs and alignment with the right partners will be key to supporting long-term deployment.”

For more information, visit the company’s website at www.AmericanFusionEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to AMFN are available in the company’s newsroom at https://ibn.fm/AMFN

• Frontieras notes milestone moment: groundbreaking of facility based on a new industrial model built on extracting the full value of coal.
• The company’s proprietary approach reframes coal as a versatile raw material capable of producing a wide spectrum of outputs through controlled processing.
• At the core of this strategy is Frontieras’s FASForm(TM) process, a solid carbon fractionation technology that separates coal into its constituent components.

Recent geopolitical conflict and supply disruptions have underscored how vulnerable global energy systems remain, with oil markets particularly exposed to shocks that can ripple through economies and industries almost instantly. The current situation has renewed the urgency of finding new approaches to domestic, feedstock-driven energy production are gaining urgency. Frontieras North America is advancing one such model through its proprietary technology that transforms coal into fuels, hydrogen and industrial products, positioning the resource as a strategic alternative in a constrained energy environment.

“On February 28, the United States and Israel launched strikes on Iran,” a recent Frontieras release, written by CEO Matt McKean, states. “Within days, the Strait of Hormuz was closed. Twenty percent of the world’s seaborne oil disappeared from the market overnight. Brent crude blew past $120 a barrel. Diesel prices across America surged more than 50% year over year. Fertilizer markets seized. Nations began rationing fuel. The International Energy Agency called it the largest supply disruption in the history of the global oil market.

“That phrase is worth sitting with,” McKean continued. “Not the largest disruption in a decade. Not the largest since the Gulf War. The largest in history.”

McKean goes on to focus on a key milestone for the company: the physical and strategic groundwork being laid for its first commercial-scale facility. The company broke ground on the facility this month, with McKean noting that “we’re not just breaking ground on a project, we’re breaking ground on an industry”—framing the moment as the beginning of a new industrial model built on extracting the full value of coal. 

According to Frontieras, traditional coal use has long focused on a single outcome: burning it for heat or electricity. This approach leaves much of coal’s inherent chemical and economic value untapped. The company’s proprietary approach reframes coal as a versatile raw material capable of producing a wide spectrum of outputs through controlled processing.

At the core of this strategy is Frontieras’s FASForm(TM) process, which the company describes as a solid carbon fractionation technology that separates coal into its constituent components. “What Frontieras is building in Mason County is not a coal mine,” McKean explains. “It is not a power plant. It is not a refinery in the traditional sense. 

“It is the first commercial-scale deployment of FASForm Solid Carbon Fractionation, a patented, zero-waste process that takes coal and disassembles it at the molecular level into multiple higher-value products: ultra-low sulfur diesel, naphtha, purified solid carbon fuel, hydrogen, ammonium sulfate fertilizer, and industrial chemicals,” he continued. “No combustion. No emissions from the process itself. Six product streams from a single feedstock, produced entirely from American resources on American soil.”

This process produces liquid fuels such as diesel, jet fuel and naphtha, as well as hydrogen and a purified carbon product. The company emphasizes that these outputs are generated in a continuous process designed to maximize yield and eliminate waste streams, positioning coal as a multiproduct industrial input rather than a single-use fuel. This capability allows one feedstock to support multiple markets simultaneously, including transportation fuels, industrial gases and materials.

This strategic approach treats coal not as a declining or problematic resource but as an underutilized one. Frontieras’s model is built on unlocking what coal already contains rather than compensating for its limitations. This perspective aligns with broader data on global reserves. According to the U.S. Energy Information Administration, proven recoverable coal reserves total about 1.16 trillion short tons worldwide, underscoring the scale and longevity of the resource. By applying a process that extracts multiple outputs from each ton, the company is effectively increasing the economic value of existing reserves without requiring new feedstocks.

The recent Frontieras report also notes the infrastructure implications of this model. Frontieras is not building isolated facilities but is designing its systems to integrate with existing coal supply chains and energy infrastructure. The company describes how its technology can be deployed in regions with established mining operations, transportation networks and industrial demand, allowing those ecosystems to evolve rather than be replaced. This approach reflects a broader industrial strategy in which legacy assets are reconfigured into higher-value production hubs rather than phased out.

A central theme of Frontieras is scale. The company outlines its plan to develop large, commercially viable facilities capable of processing thousands of tons of coal per day. These plants are designed to operate continuously and generate multiple revenue streams from a single input, which the company positions as a key differentiator. The ability to produce fuels, hydrogen and carbon products simultaneously would allow each facility to serve multiple markets, reducing reliance on any single commodity cycle and improving overall economic resilience.

Frontieras also connects its work to the growing demands of modern industry. The report points to the rising need for consistent, high-density energy and industrial inputs driven by advanced manufacturing, computing and large-scale infrastructure. This demand profile favors systems that can deliver steady output at scale. By producing fuels and hydrogen alongside solid carbon products, the company is aligning its model with sectors that require both energy and materials, including refining, transportation and heavy industry.

The environmental outcomes of the process are addressed as a function of its design rather than its primary objective. The company notes that FASForm operates as a closed-loop system that captures and repurposes byproducts, resulting in zero waste and significantly reduced emissions compared to conventional coal combustion. Sulfur and other compounds are removed during processing and converted into usable products, further reinforcing the idea that the process is built around maximizing value rather than managing waste. In this context, efficiency and emissions improvements emerge as direct consequences of a more complete utilization of the feedstock.

Frontieras’s initial project is the first step in a broader expansion strategy. The company anticipates replicating its model in multiple locations, particularly in regions where coal resources and industrial demand intersect. This suggests a scalable platform rather than a single-site operation, with the potential to establish a network of facilities that collectively redefine how coal is used in the modern economy.

By focusing on what coal can produce rather than how it has traditionally been used, Frontieras North America is articulating a distinct position within the energy and industrial landscape. As the company moves from concept to construction and eventually to operation, it is positioning itself as a developer of integrated energy and materials systems built on one of the world’s most abundant resources.

For more information, visit www.Frontieras.com.  

NOTE TO INVESTORS: The latest news and updates relating to Frontieras are available in the company’s newsroom at https://ibn.fm/Frontieras

• For a long time, proton therapy wasn’t available for many cancer patients due to the footprint of traditional proton therapy equipment and the high costs associated with it.
• However, the size and cost of this equipment is shrinking, opening it up as a more viable treatment option for cancer patients.
• Liora Technologies, a subsidiary of LIXTE Biotechnology Holdings, Inc., is poised to offer compact, precise, and accessible proton therapy through the innovative Linac for Image Guided Hadron Therapy (“LiGHT”) System.

Proton therapy is a specialized cancer treatment that uses precision-guided radiation beams to target and destroy tumors while limiting harm to surrounding healthy tissue. While it has been around for decades, it’s been largely inaccessible for many cancer patients due to both the huge footprint of traditional proton therapy equipment and the high costs. However, some programs have recently turned their heads to proton therapy and are attempting to make it more accessible for those who can benefit from it.

For example, Stanford School of Medicine recently opened a new facility that offers proton therapy that’s more accessible than in the past. Working alongside medical tech companies, the university was able to shrink down the size and cost of the proton therapy equipment, making it easier for more people to access.

In addition to Stanford, companies such as Liora Technologies are also looking to make proton therapy a more accessible and viable treatment option for the patient population. Liora Technologies, a UK-based subsidiary of LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), that is pioneering the electronically controlled therapy that represents a shift in proton delivery.

The system, called the Linac for Image Guided Hadron Therapy (“LiGHT”) system, is a compact and modular platform that uses an electronically-controlled beam to minimize proton loss and speed up energy switching, to provide a more efficient treatment. The LiGHT system is also smaller in size, more affordable, and quicker to deploy than traditional proton therapy systems.

The system also complements LIXTE’s lead clinical candidate, called LB-100. LB-100 is a protein phosphatase 2A (“PP2A”) inhibitor that is designed to enhance the effectiveness of treatments like chemotherapy and immunotherapy by preventing the cancer cells from repairing themselves from the damage caused by these therapies.

Together, the pair combine to make a more effective treatment as the LB-100 makes cancer cells more vulnerable to radiation, and the LiGHT system delivers high-precision radiation only where it needs to go.

About LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT)

LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical company that’s developing differentiated cancer therapies. Instead of introducing standalone treatments, the company focuses on a first-in-class approach that aims to enhance the effectiveness of established cancer therapies. Specifically, LIXTE’s work centers on improving how chemotherapy and immunotherapy perform in difficult-to-treat cancers with unmet medical need.

For more information, visit the company website at https://lixte.com 

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT 

Disseminated on behalf of Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF)and may include paid advertising.

• The company is advancing its Murdock Mountain phosphate project in Nevada with a focus on direct-application organic fertilizer.
• Rising oil and natural gas prices are increasing pressure on conventional fertilizer markets, many of which depend on fossil fuel elements and energy-intensive processing.
• Fertilizer prices have surged in 2026 amid the Middle East conflict and disruptions to shipping through the Strait of Hormuz.
• Nevada Organic Phosphate’s model centers on raw phosphate requiring simple grinding and bagging rather than energy and fossil fuel intensive chemical processing.
• The company is targeting the entire U.S. agricultural market, particularly the expanding organic and regenerative farming sectors.

The fertilizer industry, where oil and natural gas often play a central role in production, is highly sensitive to fluctuations in energy markets. Conventional urea and ammonia based nitrogen fertilizers are among the most energy-intensive to produce, relying heavily on natural gas as both a fuel and a source of hydrogen. When oil and gas markets tighten, fertilizer production costs often rise in parallel.

That dynamic has become more pronounced in 2026. Fertilizer markets have been disrupted following the conflict in the Middle East and associated shipping interruptions in the Strait of Hormuz, a corridor through which roughly one-third of global seaborne fertilizer trade moves, according to reporting by CNBC (https://ibn.fm/b5HOK). Fertilizer prices have risen sharply since the start of the conflict, with urea prices in some markets reportedly climbing from roughly $400–$490 per metric ton to approximately $700. Oxford Economics estimates urea and ammonia prices have surged by 50% and 20%, respectively, since hostilities began.

Global fertilizer supply has also tightened due to shutdowns of regional production facilities and export restrictions in China. These disruptions are raising concerns around food security and farmer input costs during key planting seasons.

Against that backdrop, Nevada Organic Phosphate (CSE: NOP) (OTCQB: NOPFF), a B.C.-based leader in organic sedimentary phosphate exploration, is positioning itself around a different model: supplying naturally occurring phosphate fertilizer which, unlike conventional synthetic alternatives, requires simple grinding and bagging. The Vancouver-based company is focused on advancing its Murdock Mountain phosphate project in northeastern Nevada, where it aims to produce raw organic phosphate fertilizer for U.S. agriculture. 

Unlike synthetic fertilizers that require substantial chemical conversion, the company intends to market phosphate material that can be mined, ground, bagged and shipped for direct field application, helping to reduce dependence upon volatile fossil fuel markets. This distinction is increasingly relevant as elevated oil and gas prices persist. 

Farmers in North America remain exposed to global fertilizer pricing despite domestic fossil fuel and fertilizer production. According to the U.S. Fertilizer Institute, around a third of nitrogen, phosphate and potash fertilizers used in the United States are imported. That leaves U.S. agriculture vulnerable when international supply chains are disrupted. Even in North America, where domestic oil production remains significant, producers may be incentivized to export supply into higher-priced global markets, contributing to tighter domestic pricing conditions.

Higher fertilizer costs can affect planting decisions, reduce margins for growers, and contribute to inflation in food prices. Moreover, for producers focused on organic agriculture, an expanding market, the challenge can be greater still, since certified organic operations require approved nutrient inputs that meet stricter regulatory standards. 

Nevada Organic Phosphate is unique in offering a way to deal with both inflationary fuel issues and the growing market for organic foods. The company intends to serve the broader U.S. market while also serving the growing North American organic food sector, which it estimates at approximately $35 billion.

Nevada Organic Phosphate’s primary asset is the Murdock Mountain phosphate target zone in Elko County, Nevada. The company has outlined an Exploration Target Mineral Inventory estimate of 10 million to 46 million tonnes for the main target area, with phosphate grades ranging from 3% to 15% P₂O₅. Additional target zones identified nearby could increase overall exploration potential materially, according to company disclosures.

NOP has continued advancing the project through drilling and fieldwork, with the company reporting in April that it remains on track for its 2026 drill program. Recent assay work has also suggested weighted average phosphate grades above 10% P₂O₅ in portions of the Upper Phosphatic Zone, alongside multi-nutrient chemistry supportive of soil-conditioning applications.

Beyond current geopolitical disruptions, Nevada Organic Phosphate may also be aligned with longer-term agricultural shifts. Farmers and policymakers are increasingly focused on regenerative agriculture, soil health, and reducing runoff from synthetic chemical fertilizers. Direct-application phosphate products fit within that broader movement toward alternative nutrient strategies.

As the company moves toward initial production, its focus on minimally processed phosphate fertilizer places it within a part of the agricultural supply chain that may draw increased investor attention should fertilizer inflation remain elevated and food security concerns continue to build.

For more information, visit the company’s website at www.NevadaPhosphate.com.

NOTE TO INVESTORS: The latest news and updates relating to NOP are available in the company’s newsroom at https://ibn.fm/NOP 

• A recent Zacks Small-Cap Research report outlines a number of key milestones that position Soligenix for a potentially eventful period ahead.
• One of the most notable elements highlighted in the analysis is the strength of the interim data trends observed thus far in the FLASH2 study.
• Beyond the phase 3 program, the report highlights additional clinical and scientific developments that contribute to the depth of Soligenix’s pipeline.

Independent research coverage can play a meaningful role in shaping how emerging biotechnology companies are evaluated, particularly when it brings together clinical progress, financial positioning and forward-looking milestones into a cohesive outlook. A recent analysis from Zacks Small-Cap Research provides that perspective for Soligenix (NASDAQ: SNGX), offering a detailed review of the company’s pipeline, upcoming catalysts and valuation potential while reinforcing the credibility of its development strategy.

The report outlines a number of key milestones that position Soligenix for a potentially eventful period ahead. According to the analysis, the company is advancing its phase 3 FLASH2 clinical trial evaluating HyBryte(TM) for the treatment of cutaneous T-cell lymphoma, with an interim analysis expected in the second quarter of 2026 and topline results anticipated in the second half of the year. These milestones are significant because late-stage clinical readouts often represent transformational inflection points for biotechnology companies, particularly when they involve therapies targeting conditions with limited treatment options.

One of the most notable elements highlighted in the analysis is the strength of the interim data trends observed thus far in the FLASH2 study. The report notes that the overall blinded aggregate response rate for patients who have completed the treatment phase continues to remain consistent with the 48% previously reported , compared to a 25% aggregate response rate that was originally used to power the study. This difference is meaningful because it suggests that the therapy may be outperforming initial expectations, which in turn increases confidence that the study could ultimately produce positive results.

The analysis further explores what this blinded response rate could imply. Based on the assumptions used in the study design, including a projected 40% response rate in the treatment arm and 10% in the placebo arm, the report indicates that a 48% blended response rate may point to substantially stronger performance in the active treatment group. While the exact breakdown remains unknown until data are unblinded, the interpretation offered in the report underscores why the interim data are viewed as encouraging.

Beyond the phase 3 program, the report highlights additional clinical and scientific developments that contribute to the depth of Soligenix’s pipeline. The company is planning to initiate a phase 2 clinical trial of SGX945 for Behçet’s disease following completion of reformulation work expected in the second half of 2026. This program represents an expansion of the company’s focus on rare inflammatory diseases and reflects its broader strategy of developing therapies for conditions with unmet medical need.

The analysis also draws attention to recently published data comparing HyBryte to Valchlor in the treatment of cutaneous T-cell lymphoma. According to the report, 60% of patients treated with HyBryte achieved the defined level of treatment success compared to 20% of patients treated with Valchlor over a 12-week period. Although the study was small and not statistically powered, the findings provide additional support for the therapy’s potential efficacy and tolerability profile.

Market opportunity is another area emphasized in the report. The analysis estimates that the global market for cutaneous T-cell lymphoma treatments is approximately $250 million, noting that current treatment options are often limited by suboptimal efficacy or significant side effects. This context is important because it highlights the potential commercial relevance of a new therapy that can offer improved outcomes or a better safety profile.

Regulatory progress is also identified as a key component of Soligenix’s advancement. The report confirms that SGX945 has received orphan drug designation from the European Commission and Promising Innovative Medicine designation from the UK Medicines and Healthcare products Regulatory Agency. These designations are significant because they can provide development incentives, regulatory guidance and potential pathways to earlier patient access, particularly in rare disease settings.

From a financial perspective, the report provides a snapshot of the company’s current position and projected runway. Soligenix reported research and development expenses of $7.5 million in 2025, compared to $5.2 million in 2024, reflecting increased investment in clinical programs . The company ended 2025 with approximately $7.9 million in cash and cash equivalents, which the analysis estimates will fund operations into the fourth quarter of 2026. These figures provide important context for understanding how the company plans to support its ongoing development activities.

Valuation is another central component of the report’s conclusions. Using a probability-adjusted discounted cash flow model that incorporates potential future revenues from HyBryte, SGX302 and SGX945, the analysis assigns a valuation of $20 per share. The report notes that this valuation is dependent on continued clinical success, reinforcing the importance of upcoming trial results and regulatory milestones.

This recent Zacks report analysis presents a comprehensive view of Soligenix as a company entering a period defined by clinical catalysts, regulatory progress and pipeline expansion. By highlighting both the opportunities and the risks inherent in drug development, the report provides a balanced perspective that underscores the importance of continued execution.

For Soligenix, the significance of this type of independent analysis lies not only in the validation it can provide but also in the clarity it brings to complex scientific and financial developments. As the company moves toward key clinical readouts and continues to advance its rare disease programs, the insights outlined in the report help frame the potential impact of those milestones on both the company’s trajectory and the broader effort to develop new therapies for patients with limited treatment options.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising.

• Powermax Minerals is building a portfolio of rare earth element (“REE”) exploration assets across Canada and the United States.
• Global REE demand is projected to triple by 2035, driven by a variety of growing defense and commercial needs, including electric vehicles, wind power, and AI semiconductor growth.
• China controls roughly 60% of global REE mining and 90% of processing, creating serious supply chain vulnerabilities for Western economies.
• North American governments are deploying over $1 billion in funding and incentives to develop domestic REE supply chains.
• Powermax’s projects in Ontario, British Columbia, and Wyoming offer promising opportunities in multiple deposit types and jurisdictions.

The rare earth elements (“REE”) market has moved from a niche segment of the mining industry to a strategic focal point for governments and investors. Against that backdrop, Powermax Minerals (CSE: PMAX) (OTCQB: PWMXF), a Canadian mineral exploration company focused on rare earth projects across North America, is positioning itself as a key exploration-stage participant seeking exposure to a supply chain increasingly shaped by geopolitics and industrial demand.

REEs, a group of 17 elements used in magnets, batteries and electronics, are essential inputs for defense systems, as well as electric vehicles, wind turbines, and semiconductors, the latter growing due to increased AI demand. Their role in these sectors has turned them into a critical link between energy transition policies and advanced manufacturing.

Industry forecasts suggest that global REE demand could rise from approximately 59,000 tonnes in 2022 to 176,000 tonnes by 2035. That trajectory is largely tied to accelerating electric vehicle adoption and expansion in renewable energy infrastructure. Market data compiled by industry analysts indicates the global REE market was valued at about $3.95 billion in 2024 and is expected to reach $6.3 billion by 2030, implying an annual growth rate near 8.6%.

At the same time, supply remains highly concentrated. China accounts for roughly 60% of global REE production and close to 90% of processing capacity. That imbalance has prompted policy responses in North America and Europe, where governments are seeking to reduce reliance on Chinese supply chains.

Recent measures include export controls from China and countermeasures from the United States, including funding initiatives and minimum pricing mechanisms aimed at encouraging domestic production. Canada has also updated its Critical Minerals List in 2024, placing REEs among its priority resources, while bilateral agreements such as the Energy Resource Governance Initiative are designed to align supply chain development across allied nations.

Eligibility for such programs could provide non-dilutive funding opportunities for exploration companies operating in these jurisdictions. At the same time, regulatory changes are tightening supply chains. For example, U.S. Department of Defense rules set to take effect in 2027 will restrict sourcing of certain rare earth magnets from countries including China and Russia, potentially reshaping procurement strategies.

Powermax’s approach reflects a portfolio model rather than a single-asset bet. The company holds interests in several REE exploration projects across North America, including the Atikokan project in Ontario, the Cameron project in British Columbia, and the Ogden Bear Lodge project in Wyoming. It has also outlined exploration plans for the Pinard project in northern Ontario. This geographic spread offers exposure to multiple geological settings and regulatory regimes, while also aligning with jurisdictions considered supportive of mining development.

The Atikokan REE project in northwestern Ontario represents one of the company’s more data-rich assets. Geochemical analysis from the Ontario Geological Survey, based on a dataset of more than 48,000 samples, identified several REE anomalies in the 99th percentile. Notably, multiple samples exceeding 500 parts per million of total rare earth elements were concentrated within the White Otter target area. These anomalies are supported by additional indicators, including radiometric and magnetic data, as well as the presence of pathfinder elements such as niobium, yttrium and zirconium.

The geological interpretation points toward REE-rich pegmatite systems associated with the White Otter Batholith. The distribution of anomalies across a broad area suggests district-scale potential, though the project remains at an early exploration stage.

In British Columbia, the Cameron REE project has undergone more recent fieldwork. Exploration activities conducted in 2023 included geological mapping, geochemical sampling and airborne geophysical surveys. Rock samples returned total REE values ranging from 12.46 parts per million to 1,426.83 ppm, with cerium emerging as the dominant element.

The identification of multiple areas of interest through geophysical surveys has led to the delineation of potential drill targets. Infrastructure access is relatively favorable, with proximity to highways and established mining communities in the Kamloops region. While the grades observed in early sampling vary widely, the presence of REE mineralization across multiple zones provides a basis for further exploration.

Powermax’s Ogden Bear Lodge project in Wyoming offers a different type of strategic positioning. The property borders the Bear Lodge Critical Rare Earth Project being advanced by Rare Element Resources, which has received significant financial backing, including more than $24 million from the U.S. Department of Energy and a potential $553 million financing package from the Export-Import Bank of the United States.

That adjacent development has already attracted over $170 million in investment and includes ongoing work on REE processing capabilities. For Powermax, proximity to a project with federal funding and established exploration data may reduce geological uncertainty while increasing the potential relevance of its own land position.

For more information, visit the company’s website at www.PowermaxMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to PWMXF are available in the company’s newsroom at https://ibn.fm/PWMXF

Exploration Target Cautionary Statement

The exploration targets discussed are conceptual, and there is currently not enough data to confirm a mineral resource. Further exploration may not yield successful results.

Disseminated on behalf of  ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF)and may include paid advertising.

• ESGold Corp., a development-stage company committed to the acquisition, exploration, and development of high-quality mineral properties worldwide, continues with the development of its Montauban property.
• Despite expected volatility, gold prices remain stellar, approximately twice as high as two years ago.
• Initial findings at the company’s Montauban project revealed deep and expanding mineralized corridor, over 2 kilometers of strike length.

ESGold (CSE: ESAU) (OTCQB: ESAUF), a development-stage company committed to acquiring, exploring, and developing high-quality mineral properties worldwide, continues moving forward with operations, even with expected volatility from unpredictable geopolitical events. Underlying debt and economic uncertainties are seen as long-term drivers of gold and silver prices, and show no signs of abating. 

“Gold’s push above $4,800 reflects a recalibration of risk, rather than a full regime shift,” noted Ahmad Assiri, a strategist at Pepperstone Group Ltd. “The move higher suggests markets are now pricing in a lower probability of prolonged disruption while still retaining a meaningful discount versus the pre-Iran setup,” he added (https://ibn.fm/qIJJp).

ESGold remains optimistic that gold’s stellar price will continue, given ongoing world debt and political pressures. Even with volatility, the price of gold is holding approximately twice as high as it was two years ago. As a result, ESGold is doubling down on the development of its Montauban Gold-Silver Project in Québec. In March, the company closed a C$7.2 million offering that involved the sale of 10,683,000 units at C$0.68 per unit. Proceeds from the offering being directed toward advancing the Montauban project, as well as general working capital and corporate purposes.

“This next phase marks an important step in defining the full scale of Montauban,” noted Gordon Robb, ESGold’s CEO (https://ibn.fm/iM6Ju).

The company is already undertaking a 70-square-kilometer district-scale Ambient Noise Topography (“ANT”) survey at the Montauban project. This marks the second phase of the survey, building on initial findings that revealed a deep and expanding mineralized corridor extending to approximately 900 meters and over at least 2 kilometers of strike length. Once finalized, the survey will help define high-priority drill targets for future exploration while further assessing the size, shape, and continuity of mineralized anomalies on the property.

For company information, visit the company’s website at www.ESGold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF